Afficher la notice abrégée

dc.contributor.authorMalik, Navdeep
dc.contributor.authorKim, Young-Im
dc.contributor.authorYan, Hualong
dc.contributor.authorTseng, Yu-Chou
dc.contributor.authordu Bois, Wendy
dc.contributor.authorAyaz, Gamze
dc.contributor.authorTran, Andy
dc.contributor.authorVera Ramírez, Laura 
dc.contributor.authorYang, Howard
dc.contributor.authorMichalowski, Aleksandra
dc.contributor.authorKruhlak, Michael
dc.contributor.authorLee, Maxwell
dc.contributor.authorHunter, Kent
dc.contributor.authorHuang, Jing
dc.date.accessioned2026-02-16T12:34:14Z
dc.date.available2026-02-16T12:34:14Z
dc.date.issued2023
dc.identifier.citationPublished version: Malik N, Kim YI, Yan H, Tseng YC, du Bois W, Ayaz G, Tran AD, Vera-Ramirez L, Yang H, Michalowski AM, Kruhlak M, Lee M, Hunter KW, Huang J. Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer. Cancer Res. 2023 Apr 14; 83(8): 1280-1298. doi: 10.1158/0008-5472.CAN-22-2525es_ES
dc.identifier.issn1538-7445
dc.identifier.issn0008-5472
dc.identifier.urihttps://hdl.handle.net/10481/111043
dc.descriptionThis research was supported by the Intramural Research Program of the NIH, 1ZIABC011158- 12 and 1ZIABC011504-08, to J Huang. The authors would like to thank Drs. Alana Welm for the PDX model, Richard Youle for the discussion on mitophagy, Ferri Soheilian for electron microscopy, and Brandi Carofino for scientific editing.es_ES
dc.description.abstractUnderstanding functional interactions between cancer mutations is an attractive strategy for discovering unappreciated cancer pathways and developing new combination therapies to improve personalized treatment. However, distinguishing driver gene pairs from passenger pairs remains challenging. Here, we designed an integrated omics approach to identify driver gene pairs by leveraging genetic interaction analyses of top mutated breast cancer genes and the proteomics interactome data of their encoded proteins. This approach identified that PIK3CA oncogenic gain‐of-function (GOF) and CBFB loss‐of‐function (LOF) mutations cooperate to promote breast tumor progression in both mice and humans. The transcription factor CBFB localized to mitochondria and moonlighted in translating the mitochondrial genome. Mechanistically, CBFB enhanced the binding of mitochondrial mRNAs to TUFM, a mitochondrial translation elongation factor. Independent of mutant PI3K, mitochondrial translation defects caused by CBFB LOF led to multiple metabolic reprogramming events, including defective oxidative phosphorylation, the Warburg effect, and autophagy/mitophagy addiction. Furthermore, autophagy and PI3K inhibitors synergistically killed breast cancer cells and impaired the growth of breast tumors, including patient‐derived xenografts carrying CBFB LOF and PIK3CA GOF mutations. Thus, our study offers mechanistic insights into the functional interaction between mutant PI3K and mitochondrial translation dysregulation in breast cancer progression and provides a strong preclinical rationale for combining autophagy and PI3K inhibitors in precision medicine for breast cancer.es_ES
dc.description.sponsorshipIntramural Research Program of the NIH (1ZIABC011158-12 and 1ZIABC011504-08)es_ES
dc.language.isoenges_ES
dc.publisherAmerican Association for Cancer Researches_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleDysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast canceres_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1158/0008-5472.CAN-22-2525
dc.type.hasVersionAOes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional